重组人血管内皮抑制素联合TP方案在晚期EGFR野生型肺鳞状细胞癌患者的疗效观察  

Efficacy of recombinant human endostatin combined with TP regimen on patients with advanced EGFR wild type squamous cell lung carcinoma

作　　者：王伟[1] 任必勇[1] 

机构地区：[1]重庆三峡中心医院肿瘤呼吸病区,404000

出　　处：《国际肿瘤学杂志》2017年第10期745-748,共4页Journal of International Oncology

摘　　要：目的探讨重组人血管内皮抑制素联合TP方案（紫杉醇＋顺铂）治疗晚期表皮生长因子受体（EGFR）野生型肺鳞状细胞癌的疗效。方法选取2012年1月至2015年2月在重庆三峡中心医院就诊的肺鳞状细胞癌患者100例为研究对象，根据治疗方法分为单纯组（n=50）和联合组（n=50），单纯组使用TP方案，联合组在TP方案的基础上使用重组人血管内皮抑制素。依据实体瘤疗效评价标准1．1版（RECIST1．1）进行治疗效果评价，并分析近期疗效、远期疗效、不良反应、住院时间及住院费用。结果联合组患者的客观有效率为52．0％（26／50），明显高于单纯组的16．0％（8／50），差异有统计学意义（x2=14．429，P=0．007）。联合组患者的疾病控制率明显高于单纯组（80．0％552．0％），差异有统计学意义（X2=8．734，P=0．009）。与单纯组患者相比，联合组患者的中位无进展生存期（8．4个月：6．3个月）和总生存期（17．7个月：11．5个月）明显延长，差异有统计学意义（X2=5．390，P=0．025；X2=3．993，P=0．035）。单纯组患者的各种不良反应发生率与联合组基本一致，差异无统计学意义（均P〉0．05）。与单纯组相比，联合组患者住院时间明显延长[（23．5±2．8）周：（18．2±3．5）周]，住院费用明显增加[（112453．9±994．9）元：（87821．4±943．2）元]，差异有统计学意义（t=8．361，P〈0．001；t=127．051，P〈0．001），但联合组患者满意度显著高于单纯组患者（88．0％：64．o％，r=4．210，P=0．017）。结论应用重组人血管内皮抑制素联合TP方案治疗晚期EGFR野生型肺鳞状细胞癌效果较好，不良反应发生率低，适于临床推广应用。Objective To evaluate the efficacy of recombinant human endostatin combined with TP （paclitaxel ＋ cisplatin） in the treatment of advanced epidermal growth factor receptor （EGFR） squamous cell lung carcinoma. Methods From January 2012 to February 2015, 100 patients with squamous cell lung carci- noma in Chongqing Three Gorges Central Hospital for medical treatment were selected as the subjects. Accor- ding to different treatment methods, they were divided into single group （ n = 50） and combined group （ n = 50）. The single group used the TP protocol and the combined group was treated with recombinant human en- dostatin on the basis of the TP protocol. The therapeutic effect was evaluated according to the Response Evalua- tion Criteria In Solid Tumors 1.1 （ RECIST 1.1 ）. The short-term effects, long-term effects, adverse reactions, hospitalization time and expenses were also analyzed. Results The objective effective rate in the combined group [52.0% （26/50） ] was significantly higher than that in the single group [ 16.0% （8/50） ], with a sig- nificant difference （X2 = 14. 429, P = 0. 007 ）. The disease control rate in the combined group was higher than that in the single group （ 80.0% vs. 52.0% ）, with a significant difference （X2 = 8. 734, P = 0. 009 ）. Com- pared with the patients in the single group, the median progression free survival （8.4 months vs. 6.3 months） and overall survival （ 17.7 months vs. 11.5 months） in the combined group were prolonged obviously, with sig- nificant differences （X2 = 5. 390, P = 0.025 ; X2 = 3. 993, P = 0. 035 ）. The incidence rates of adverse reactionsin single group were basically the same compared with the combined group, and the difference was not statisti- cally significant （all P 〉 0.05）. Compared with the single group, the hospitalization time in combined group was longer [ （23.5 ±2.8） weeks vs. （18.2± 3.5 ） weeks], and the expenses in combined group was higher [ （ 112 453.9 ± 994.9） yuan vs. （ 87

关 键 词：肿瘤 鳞状细胞 肺肿瘤 血管抑制素类 顺铂 紫杉醇 

分 类 号：R734.2[医药卫生—肿瘤]